OBJECTIVE: To probe into the efficacy and safety of Lianhua Qingwen granules combined with lopinavir/ritonavir in the treatment of COVID-19. METHODS: Clinical data of 50 patients with COVID-19 who were treated with Lianhua Qingwen granules combined with lopinavir/ritonavir tablets were retrospectively selected until Mar. 24

2020 in Lu’an Hospital Affiliated to Anhui Medical University. Changes of clinical symptoms

imaging examination and laboratory examination before and after treatment and incidence of adverse drug reactions were summarized and analyzed. RESULTS: The clinical symptoms of 50 patients were significantly improved after treatment with Lianhua Qingwen granules combined with lopinavir/ritonavir. The results of lung imaging examination showed that the average improvement time was（ 10. 83 ± 5. 91） d. After 7 d of treatment

the number of patients with normal indicators（ including white blood cells

lymphocytes

alanine aminotransferase

aspartic acid aminotransferase

creatine kinase

lactate dehydrogenase and C-reactive protein） increased compared with those before treatment

and the improvement of C-reactive protein level was the most significant. Adverse drug reactions occurred in 24 of the 50 patients

most of which were mild and all resolved after symptomatic treatment. CONCLUSIONS: In the absence of specific therapeutic drugs for COVID-19

Lianhua Qingwen granules combined with lopinavir/ritonavir can be used as an empirical choice for clinical treatment. Adverse drug reactions should be closely monitored during the medication process to ensure the medication safety.